Want to see UNCY full AI Analyst Report?
Top Page
Unicycive Therapeutics
(NASDAQ:UNCY)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.50
▼(-36.01% Downside)
Action:Reiterated
Date:10/14/26
The score is primarily held down by weak financial performance (zero revenue, sizable losses, and ongoing cash burn), which outweighs balance-sheet improvements. Technicals also detract due to a clear downtrend despite oversold readings. Corporate events are mixed, with a constructive NDA resubmission offset by litigation risk, while valuation metrics offer limited support given continued unprofitability.
Positive Factors
Regulatory Progress
Resubmission with a new FDA-rated manufacturing vendor directly addresses deficiencies cited in prior CRLs, while stability and bridging data support the revised filing. This improves regulatory execution and preserves a path toward commercialization, although approval is not assured.
Negative Factors
No Current Revenue
The absence of current revenue confirms that Unicycive remains dependent on successful development and eventual commercialization of its pipeline. Persistent large losses also show that the business has not yet demonstrated operating leverage, making future earnings highly contingent on regulatory and launch execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
Resubmission with a new FDA-rated manufacturing vendor directly addresses deficiencies cited in prior CRLs, while stability and bridging data support the revised filing. This improves regulatory execution and preserves a path toward commercialization, although approval is not assured.
Read all positive factors
Unicycive Therapeutics (UNCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$112.81M
Dividend YieldN/A
Average Volume (3M)850.38K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue GrowthN/A
EPS Growth43.63%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.67
Shares Outstanding27,855,257
10 Day Avg. Volume1,010,194
30 Day Avg. Volume850,382
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.92
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-310.69
Enterprise Value/Ebitda-1.90
Forecast
1Y Price Target
$25.50Price Target Upside366.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$367.00K
Unicycive Therapeutics Business Overview & Revenue Model
Company Description
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patien...
Unicycive Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 675.00K | 951.00K | 0.00 |
| Gross Profit | -211.00K | -572.00K | 0.00 | 675.00K | 951.00K | 0.00 |
| EBITDA | -34.52M | -25.91M | -36.23M | -30.18M | -17.89M | -9.38M |
| Net Income | -35.22M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M |
Balance Sheet | ||||||
| Total Assets | 72.03M | 49.13M | 31.67M | 14.19M | 2.82M | 18.74M |
| Cash, Cash Equivalents and Short-Term Investments | 61.42M | 41.27M | 26.14M | 9.70M | 455.00K | 16.58M |
| Total Debt | 671.00K | 199.00K | 773.00K | 811.00K | 201.00K | 335.00K |
| Total Liabilities | 18.76M | 18.94M | 24.24M | 18.00M | 3.28M | 2.26M |
| Stockholders Equity | 53.27M | 30.20M | 7.43M | -3.81M | -466.00K | 16.48M |
Cash Flow | ||||||
| Free Cash Flow | -27.85M | -31.34M | -28.65M | -18.30M | -15.65M | -5.80M |
| Operating Cash Flow | -27.84M | -31.32M | -28.57M | -18.28M | -15.65M | -5.77M |
| Investing Cash Flow | -17.25M | -12.10M | -72.00K | -12.00K | -2.00K | -29.00K |
| Financing Cash Flow | 66.95M | 46.47M | 45.09M | 27.54M | -471.00K | 22.38M |
Unicycive Therapeutics Technical Analysis
Negative
5.47
Price Trends
4.96
Negative
5.66
Negative
6.25
Negative
Market Momentum
-0.31
Positive
24.03
Positive
7.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Negative. The current price of 5.47 is above the 20-day moving average (MA) of 4.48, above the 50-day MA of 4.96, and below the 200-day MA of 6.25, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 24.03 is Positive, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNCY.
Unicycive Therapeutics Risk Analysis
Unicycive Therapeutics disclosed 56 risk factors in its most recent earnings report. Unicycive Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Unicycive Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $70.37M | 0.60 | 103.52% | ― | 15.46% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $32.19M | -0.68 | -202.14% | ― | ― | 73.69% | |
46 Neutral | $113.11M | -0.85 | -320.60% | ― | -10.30% | 84.17% | |
45 Neutral | $112.81M | -2.23 | -88.81% | ― | ― | 43.63% | |
45 Neutral | $95.11M | -5.15 | -41.15% | ― | -100.00% | 64.23% |
* Healthcare Sector Average
UNCY
Unicycive Therapeutics
3.73
-0.83
-18.20%
CVM
Cel-Sci
1.75
-8.12
-82.27%
FBIO
Fortress Biotech
1.95
-0.78
-28.57%
CBUS
Cibus
1.41
-0.06
-4.08%
EQ
Equillium
1.32
0.08
6.45%
Unicycive Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Unicycive Resubmits NDA for Kidney Disease Treatment
Positive
Sep 29, 2026
On September 29, 2026, Unicycive Therapeutics announced it had resubmitted its New Drug Application for oxylanthanum carbonate, an oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis. The resubmission follows...
Business Operations and StrategyLegal Proceedings
Unicycive Faces New Securities Class Action Over NDA Disclosures
Negative
Sep 28, 2026
On September 3, 2026, a securities class action lawsuit was filed in the United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. and certain executives, alleging violations of federal securities la...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.